---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-024496"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:59:59.958919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports Q1 net loss of $9.7M; plans Phase 3 trial for PDS0101 in Q4 2023

## Summary
- Q1 net loss $9.7M ($0.32/sh) vs $8.5M ($0.32/sh) in Q1 2022; R&D spend rose to $5.8M.
- Cash $65.2M at March 31, 2023; expected to fund operations into Q3 2024.
- VERSATILE-002 Phase 2 data to be presented at ASCO 2023; Phase 3 VERSATILE-003 initiation planned for Q4 2023.
- Received $1.4M from sale of NJ tax benefits; NCI-led triple combination trial progressing.
- Preclinical Infectimune data showing flu protection published in peer-reviewed journal.

## SEC filing metadata
- accession: 0001140361-23-024496
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/0001140361-23-024496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/brhc20052894_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-024496
- JSON: https://secwatch.observer/filing/0001140361-23-024496.json
- Plain text: https://secwatch.observer/filing/0001140361-23-024496.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported the three months ended March 31, 2023 results: net income approximately $9.7 million, EPS $0.32 per basic share and diluted share.
  - Period: the three months ended March 31, 2023
  - Net income: approximately $9.7 million
  - EPS: $0.32 per basic share and diluted share
  - Result: reported results
  source text: Reported net loss was approximately $9.7 million, or $0.32 per basic share and diluted share, for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/0001140361-23-024496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.